Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Status:
Completed
Trial end date:
2013-11-19
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab
every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from
baseline in low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic adults unable
to tolerate an effective dose of a statin (HMG-CoA (5-hydroxy-3-methylglutaryl-coenzyme A)
reductase inhibitors).